Trial Profile
An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Cephalon
- 28 Aug 2012 New trial record